For people whose endometrial cancer returns after treatment, finding another effective option can be difficult. According to results from a large Phase 3 clinical trial published in The Lancet, a new targeted drug may offer hope to patients whose cancer has progressed despite chemotherapy and immunotherapy.
In the study, patients who received the experimental drug sacituzumab tirumotecan (sac-TMT) had a better chance of living without their cancer worsening than those who received standard chemotherapy. They also lived longer overall.
The findings, published on Oct. 26, 2026, could represent a new treatment opportunity for individuals with advanced and recurrent endometrial cancer. However, the drug remains under review by the U.S. Food and Drug Administration (FDA).
What is endometrial cancer and why can advanced cases be difficult to treat?
Endometrial cancer starts in the lining of the uterus (the endometrium). The uterus is the hollow, pear-shaped organ where fetal development occurs during pregnancy. According to the National Cancer Institute (NCI), endometrial cancer is the most common type of cancer that begins in the uterus.
Many people are diagnosed before the cancer spreads beyond the uterus, when surgery alone may effectively treat the disease. When the cancer spreads to other parts of the body or returns after initial treatment, however, it becomes much harder to manage.
Patients with advanced or recurrent disease often require chemotherapy, immunotherapy, radiation or a combination of therapies. Over time, some cancers stop responding to these treatments, leaving patients with fewer effective options.
What is Sacituzumab Tirumotecan (Sac-TMT), the new targeted endometrial cancer treatment?
Sacituzumab tirumotecan, or sac-TMT, is an investigational cancer therapy being developed by Merck in partnership with Kelun-Biotech.
It belongs to a class of targeted therapies called antibody-drug conjugates (ADCs). ADCs pair a lab-made antibody with a potent cancer-killing medication. The antibody acts like a homing device, guiding the medicine directly to specific proteins on the surface of cancer cells. While this approach is designed to concentrate treatment around tumors, it does not mean the drug only affects cancer cells or avoids harming healthy tissue.
How does Sac-TMT target endometrial cancer cells?
Sac-TMT uses a monoclonal antibody that binds to TROP2 proteins on the surface of cancer cells. According to Merck, TROP2 is expressed on many endometrial cancer cells, making it a useful target for delivering therapy directly to tumors.
Once bound to TROP2, the drug is absorbed into the cancer cell, where it releases a chemotherapy payload known as a topoisomerase I inhibitor. This substance blocks an enzyme that cells need to regulate and repair their DNA, preventing the cancer cells from multiplying and causing them to die.
Researchers note that sac-TMT may also trigger a “bystander effect,” allowing the cancer-killing payload to reach neighboring tumor cells, including some with lower levels of TROP2. While this mechanism may help control tumors more broadly, its benefits and risks continue to be evaluated in clinical studies.
What did the Phase 3 TroFuse-005 clinical trial find about Sac-TMT?
The TroFuse-005 trial enrolled 776 patients with advanced or recurrent endometrial cancer whose disease had progressed after treatment with platinum-based chemotherapy and an anti-PD-1 or anti-PD-L1 immunotherapy.
A total of 386 patients were randomly assigned to receive sac-TMT, and 390 were assigned to receive standard chemotherapy (either doxorubicin or paclitaxel, chosen by their physicians).
Conducted across 242 cancer centers in 31 countries and regions, the trial measured how long patients lived without their cancer worsening (progression-free survival) as well as overall survival and tumor shrinkage.
How much did Sac-TMT reduce the risk of endometrial cancer progression and death?
The trial showed improvements across its major outcome measures for patients taking sac-TMT compared with those receiving standard chemotherapy:
- Progression-free survival: The rate of cancer progression or death was 41% lower in the sac-TMT group. Median progression-free survival was 7.2 months for patients receiving sac-TMT, compared with 3.9 months for those receiving chemotherapy.
- Overall survival: Sac-TMT lowered the risk of death by 32%. Median overall survival was 19 months in the sac-TMT group versus 12.1 months in the chemotherapy group—a 6.9-month improvement in median overall survival.
- Tumor response: Measurable tumor shrinkage occurred in 35.1% of patients treated with sac-TMT, compared with 17.3% of those who received chemotherapy.
These figures reflect differences between groups in a clinical trial and cannot predict an individual patient’s lifespan or response to treatment.
“For most patients whose cancer progresses after platinum chemotherapy and immunotherapy, the main option today is single-agent chemotherapy, such as doxorubicin or paclitaxel. There is no established standard of care,” said Domenica Lorusso, MD, PhD, professor of obstetrics and gynecology at Humanitas University in Milan and global lead investigator of the trial.
While the improvements in progression-free and overall survival are notable, researchers note that longer follow-up is needed to understand how durable these benefits remain over time.
What are the potential side effects of Sac-TMT?
Like other cancer therapies, sac-TMT carries notable side effects that patients and clinicians must weigh carefully. Common side effects in the trial included anemia, neutropenia, oral mucositis (painful inflammation and sores inside the mouth) and dry, itchy eyes.
Anemia occurs when the body lacks enough healthy red blood cells to carry adequate oxygen to tissues. According to the Cleveland Clinic, neutropenia is a drop in neutrophils, a type of white blood cell critical for fighting off infections. Both conditions require close blood-count monitoring during treatment.
Additionally, the trial showed that 69% of patients who received sac-TMT experienced at least one grade 3 or higher adverse event, compared with 57% of those treated with standard chemotherapy. Grade 3 or higher events are classified as severe or medically significant and may require targeted treatment, close monitoring or hospitalization, whether or not they are directly caused by the study drug.
Serious adverse events occurred in 35% of patients receiving sac-TMT and 32% of those receiving chemotherapy. Treatment-related deaths occurred in less than 1% of patients in either group.
It’s important to note that if a treatment is promising in terms of survival, it does not necessarily mean that it cannot cause serious side effects. Before beginning a new cancer treatment, patients should talk with their cancer team about any side effects they might expect, any blood tests they will have to take, any eye symptoms they will need to watch for and how they can help prevent infections.
Who could benefit from Sac-TMT treatment for endometrial cancer?
The TroFuse-005 trial focused on adults with advanced or recurrent endometrial cancer who had already been treated with platinum-based chemotherapy and a PD-1 or PD-L1 immunotherapy agent, including patients who had received up to three prior lines of therapy. The findings are therefore most relevant to individuals whose cancer did not respond to or returned after those treatments.
The results do not make sac-TMT a standard therapy for everyone diagnosed with endometrial cancer, nor was the drug studied as a replacement for surgery or other established treatments for early-stage disease. If approved by the FDA, sac-TMT would initially be prescribed to patients who meet the specific treatment history and disease criteria outlined on its official label.
Has the FDA approved Sac-TMT for endometrial cancer?
No. Sac-TMT is still being studied for the treatment of endometrial cancer and is not available for general use as an approved treatment.
Merck has filed a Biologics License Application, and it has been accepted for priority review. The agency has set June 15, 2027, as its target action date.
Priority review indicates that an application is reviewed by the FDA in a shorter time frame since the treatment may represent an important new option for patients. It does not imply that the agency has decided a drug is approved or that the benefits of taking the drug are greater than the risks.
The clinical evidence, safety data and other information in the application will be considered by FDA before a decision is made. Patients should not expect that sac-TMT is an approved treatment for this cancer and is available.
What could this new targeted therapy mean for the future of endometrial cancer treatment?
The TroFuse-005 findings could mark an important development for patients with advanced or recurrent endometrial cancer. It is also significant in terms of overall survival, which might be the only means of improvement, as treatment options may be exhausted after chemotherapy and immunotherapy.
In addition, sac-TMT is included in a broader research program focused on antibody–drug conjugates (ADC) targeting TROP2. Researchers are investigating if this strategy would be useful for other cancers that express the TROP2 protein.
Dr. Justus Rabach, MD, a Blavity Health medical reviewer, notes that when evaluating late-stage cancer trials, patients and clinicians have to weigh side effects against incremental survival gains: “Pinpointing cause is elusive and treatment, even when it works in one type of cancer, it does not necessarily work in other cancers. It is always a balance of risks versus benefits. Does it buy you nine months? It is yet to be determined from separate clinical trials whether it is effective and safe in each disease.”
He adds, “The TroFuse-005 study was sponsored by Merck, and some investigators disclosed institutional funding or other financial relationships with Merck. These disclosures do not necessarily make the findings invalid, but they are relevant when considering the research when paired with its published peer-reviewed version.”
How sac-TMT ultimately fits into endometrial cancer care will depend on longer-term follow-up data and the FDA’s regulatory review.
Bottom line
In a Phase 3 clinical trial, sac-TMT improved median overall survival, delayed cancer progression, and increased tumor response rates compared with standard chemotherapy in patients with previously treated advanced or recurrent endometrial cancer. While the findings are encouraging, the drug is not yet approved by the FDA, and researchers continue to evaluate its long-term safety and effectiveness.
Frequently Asked Questions
How is sac-TMT administered to patients?
In the TroFuse-005 trial, patients received sac-TMT through an intravenous infusion on days 1 and 15 of each 28-day treatment cycle.
What does FDA priority review mean?
Priority review means the FDA aims to decide on a drug application sooner than under its standard review timeline, but it does not guarantee approval.
Citations
Lorusso D, Martin-Babau J, Floor B, et al. Sacituzumab tirumotecan versus treatment of physician’s choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial. The Lancet. Published online October 26, 2026. doi:10.1016/S0140-6736(26)02099-4
National Cancer Institute . Endometrial SPOREs. Cancer.gov. March 27, 2025. Accessed November 11, 2026. https://dctd.cancer.gov/research/spores/focus-area/endometrial
Merck. Sacituzumab Tirumotecan (Sac-TMT) Reduced the Risk of Death by 32% and the Risk of Disease Progression or Death by 41% Compared to Chemotherapy in Certain Patients With Advanced or Recurrent Endometrial Cancer. Merck.com. October 26, 2026. Accessed November 11, 2026. https://www.merck.com/news/sacituzumab-tirumotecan-sac-tmt-reduced-the-risk-of-death-by-32-and-the-risk-of-disease-progression-or-death-by-41-compared-to-chemotherapy-in-certain-patients-with-advanced-or-recurrent-endometrial/
Cleveland Clinic. Neutropenia: Symptoms, Causes, Treatments. Cleveland Clinic. May 27, 2022. Accessed November 11, 2026. https://my.clevelandclinic.org/health/diseases/21058-neutropenia

